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Abstract 
A blood circulatory system (vasculature) is an essential structure in multicellular 
organisms for distribution of oxygen and nutrients. Angiogenesis, the formation and 
growth of new blood vessel sprouts from existing vessels, is the process by which 
additional vascular elements are formed from an initial vascular structure. During 
angiogenesis, endothelial cells are stimulated to exhibit migratory and proliferative 
phenotypes, leading to the formation of new vessel sprouts. Sprouting endothelial cells 
degrade their basement membrane by production of matrix metalloproteinases (MMPs ). 
In an effort to understand the role of certain MMPs during the sprouting process, the rat 
fat microvessel fragment 3D model of angiogenesis was used to immunostain for the 
presence ofMMP-2, MMP-9 and MTl-MMP at several stages of the sprouting process. 
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Background 
A blood circulatory system (vasculature) is an essential structure in multicellular 
organisms for distribution of oxygen and nutrients, thereby overcoming the limits of 
oxygen diffusion. Angiogenesis, the formation and growth of new blood vessel sprouts 
from existing vessels, is the process by which additional vascular elements are formed 
from an initial vascular plexus. During angiogenesis, previously quiescent endothelial 
cells are stimulated to exhibit migratory and proliferative phenotypes, leading to the 
formation of new vessel sprouts. Sprouting endothelial cells degrade their basement 
membrane by production of matrix metalloproteinases (MMPs) [l, 2] as well as over-
production of extracellular matrix proteins [3, 4], and form contacts with and migrate 
along extracellular matrix components [5], resulting in vessel elongation. Later, 
endothelial cells deposit a new basement membrane resulting in a patent, perfusion-
capable capillary [ 6]. The process of angiogenesis is fundamentally important to the 
formation of new vasculature during development [4, 7-9], wound healing [10-13] and 
tumorigenesis [ 6, 14-18] 
Elucidation of the mechanisms controlling microvessel sprouting and the interaction of 
microvessels with the ECM has basic scientific interest and potential clinical application. 
However, when attempting to clarify the contribution of the many processes that regulate 
angiogenesis, one is faced with the insuperable task of attempting to isolate the individual 
contribution of many inter-related biological processes. Although angiogenesis has been 
studied extensively in the context of disease and injury (e.g., [10, 14, 15, 19]), little is 
known regarding the fundamentals of vessel sprouting and elongation in a three 
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dimensional environment. Recent studies have demonstrated that biophysical aspects of 
the ECM can be as important as molecular signals in modulating angiogenesis [20-23]. 
Thus, characterization of the interactions between microvessels and the surrounding 
ECM would provide new insight into the mechanistic basis of tissue organization and its 
role in development, disease and soft tissue injury/healing. This will not only further our 
basic understanding of angiogenesis, but will also provide design principles that may be 
exploited to engineer patterned microvascular constructs with specific vessel topology. 
Tissue and organ mnmcs such as 3D in vitro models provide a unique, highly 
controllable paradigm for studying the physiology and pathophysiology of human tissues. 
In vitro models of angiogenesis based on isolated cells often do not recapitulate realistic 
sprouting and elongation. Interpretation of results is further complicated by the possibility 
of cell lineage specific behavior in the model. Our 3D in vitro model of angiogenesis is 
based on isolation and culture of microvessel fragments in a 3D collagen gel matrix [24-
28], and is most accurately described as an "organ culture" model. Unlike other 3D in 
vitro models of angiogenesis that begin with isolated endothelial cells, our model uses 
isolated microvessel fragments that include the full spectrum of vessel elements in the 
microvasculature, namely arterioles, capillaries and venules [24]. These "parent" vessels 
contain associated perivascular cells [24] and retain their basement membrane after initial 
harvest and seeding. Pericytes disassociate from the parent vessels and the endothelial 
cells. This phenomenon is consistent with the increasingly recognized role of pericytes in 
angiogenesis and observations that perivascular cell withdrawal from vessel segments 
relaxes the parent endothelial cell tube and permits sprouting and vessel elongation 
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during angiogenesis (29-33]. Sprouts elongate as patent tubes, branching and 
anastamosing with other vessels. New neovessels continue to grow into a new vascular 
network that ultimately fills the gel space by Day 10 of culture. These neovessels form a 
functional vascular tree when implanted (28] - microvascular constructs cultured for 7 
days rapidly inosculate with the recipient host circulation after implantation and begin to 
carry blood. This demonstrates that neovessels foQned via angiogenesis in the collagen 
gels remain perfusion competent and capable of progressing into a perfused network. 
Construct implantation allows the study of post-angiogenesis events. 
Collagen crosslinking 
Background and Motivation 
In an effort to understand collagen remodeling during angiogenesis, experiments were 
proposed in which collagen crosslinks were to be induced in three separate manners, 
glycation, transglutaminase, and lysyl oxidase. The intent of the experiments was to 
evaluate the endogenous optical signatures of the different crosslinking schemes using 
fluorescence spectroscopy as well as two-photon excited fluorescence (2PEF) and second 
harmonic generation (SHG). Development of endogenous optical signatures of 
crosslinked collagen would allow us to evaluate the extent of collagen crosslinking within 
a live sample thereby providing us a way to evaluate crosslinking without destruction of 
the sample which is the current standard of evaluation using chemical, enzymatic or 
mechanical means. Spectroscopy on collagen cross links has been previously used to 
quantify their presence with high pressure liquid chromatography (34], but to our 
knowledge no attempts were made to incorporate these techniques into laser scanning 
microscopy, perhaps due to the challenge of UV-excitation. Table 1 illustrates the known 
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fluorescence emission properties for collagen cross links which suggests the complexity 
of collagen fluorescence. 
~rossUnkT~ Cross Link Excitation Emission Fluor. Proposed 
max max Contrib. Excitation 
Immature Enzymic Lysinonorleucine 350 400 2PEF 
Reducible CLNL) 
Immature Enzymic Hydroxylysinenoro-leucine 350 400 2PEF 
Reducible CHLNL) 
Immature Enzymic Dehydrocylysineoroleucine 350 400 2PEF 
Reducible l(DHLNL) 
Mature Enzymic Histidino-hydroxylysinonor- unkwn unknwn 2PEF 
Hvstidine leucine CHHL) 
Mature Enzymic Pyridinium: Lysyl- 325 (290) 400 (380- 3PEF 
Pvrrole :pyrldlnollne (L-Pvr) 460) 
Mature Enzymic Pyridinium: Hydoxylysin 325 (290) 400 3PEF 
Pvrrole 'Dvridinoline lH-Pvrl 
Glycation Pentosidine 335 385 25-40% 3PEF 
Glycation Vesperlvsine A, B, C 370 440 5% 2PEF 
Glycation Lysine CrosslineA B 380 460 2PEF 
Glycatlon ArQinie Argpyrimidine 320 380 3PEF 
Table 1: Known fluorescence collagen cross links with their excitation and em1ss1on maxima. 
Tissue engineering approaches have been successful in providing histochemical as well 
as biochemical mimicry of certain tissue types including vessels [35-38], nerves [39], 
skin [40-43], cartilage [44, 45], bone [46] and ligaments [47]. Scaffolds have been 
developed with the motivation that seeded materials have a support system which 
provides cells with growth and migrational support as well as structural context. Since 
collagens are the primary component of tissues such as bone, skin, cartilage and tendons, 
they have been used extensively in biomedical tissues, particularly scaffolds. Collagen 
scaffolds have been successful but have suffered from issues related to lack of 
mechanical strength. Crosslinking of collagen is one way to increase the mechanical 
strength of collagen and has been described by many methods. Ultraviolet light [ 48-50], 
dehydrothermal treatment [50], chemical agents such as glutaraldehyde [48, 51-54], acyl 
azides [55], other chemical means [56-62], non-enzymatic glycation [57], enzymatic 
crosslinking by transglutaminase [63, 64] and overexpression of the crosslinking enzyme 
lysyl oxidase [65, 66] are among the techniques utilized. When considering the various 
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crosslinking techniques, one must consider the potential effects of cytotoxicity as a result 
of the agent used. Glutaraldehyde was shown to impart some degree of cytotoxicity when 
crosslinked prior to cell seeding [67] while transglutaminase [63, 64], lysyl oxidase [65, 
66] and glycation [57] showed no apparent cytotoxicity. The latter three methods are the 
only ones currently accepted as non-cytotoxic in the presence of cells [57, 63-66]. 
Glycation 
Type I rat tail collagen (BD Biosciences, San Jose, CA) was utilized in a final 
concentration of 3mg/mL. I .327mL collagen was combined with .2mL of I OX Hanks 
medium for a final concentration of IX Hanks, 20mM HEPES and .433mL sterile water 
for a final volume of2mL. The mixture was then pH neutralized using IM NaOH, loaded 
into 48 well plates (200µL per gel) and incubated at 37°C for 30 minutes to polymerize 
the gels. Standard MI99 reagent (GIBCO, Grand Island, New York), which has a glucose 
concentration of 5mM, was used in wells I and 2 as controls. Wells 3 and 4 were 
supplemented with I5mM glucose in MI99, wells 5 and 6 with 30mM glucose in MI99, 
and wells 7 and 8 with 50mM glucose in MI99. The gels were allowed to incubate at 4°C 
for 7 weeks. After 7 weeks, the samples were removed from the 48 well plates and placed 
in a quartz imaging chamber and subjected to fluorescence spectroscopy. 
Fluorescence spectroscopy. The fluorescence properties of the collagen gels were 
measured in a standard I cm path length quartz cuvette using a double excitation 
emission fluorometer (Fluorolog 3-22, JY Horiba, Edison, NJ). For each spectroscopic 
experiment, excitation and emission wavelengths were varied to obtain fluorescence data 
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matrices. Excitation wavelengths varied from 270 to 600 nm in increments of 10 nm 
while collecting emission data from a range starting 20 nm above the excitation 
wavelength and extending to 20 nm less than twice the excitation wavelength with 700 
nm as the maximum measured emission wavelength. Each measurement takes 
approximately 15 min to complete. Each of the three conditions was measured only once 
due to technical difficulties extracting the samples from the 48 well plates. The gels 
either tore or were stuck inside the wells. Speculation is that, either length of time or 
glucose content or the combination of both, allowed the gels to bond with the plastic 
surface of the wells. Also, when imaging was performed, the gels were slightly 
compacted in order to fit within the imaging chamber which would lead to changed 
optical characteristics as well as inconsistency. Excitation emission matrices (EEMs) 
showing the results of the three scans alone and relative to each other are shown in 
Figure 1. Preliminary analysis showed no prominent distinction between the samples but 
did show a slight difference between the 15mM scan and the 25mM scan. Since we did 
not have the requisite amount of scans for statistical analyses, we elected to continue with 
a second experimental protocol. We elected to mold the gels while in the imaging 
chamber itself then remove the gels and suspend them in the desired media. The gels 
were approximately Imm thick but proved to be too thin to transfer back into the imaging 
chamber intact after 8 weeks of incubation time resulting in no measurements being taken 
using this setup. 
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Transglutaminase 
Type I rat tail collagen (BD Biosciences, San Jose, CA) was utilized in a final 
concentration of 3mg/mL. l .327mL collagen was combined with .2mL of I OX Hanks 
medium for a final concentration of IX Hanks, 20mM HEPES and .433mL sterile water 
for a final volume of2mL. The mixture was then pH neutralized using IM NaOH, loaded 
into 48 well plates (200µL per gel) and incubated at 37°C for 30 minutes with a 5000:1 
ratio of collagen to transglutaminase enzyme as per previous work done by Orbam et al 
[64]. Recombinant human transglutaminase (rhTG2 (N-ZYME Biotech GmbH, 
Darmstadt, Germany)) was determined to be suitable for our purposes after 
correspondences to N-ZYME Biotech and was added prior to incubation. The gels were 
then analyzed using fluorescence spectroscopy within a few hours of polymerization. 
9 
e 
.s 
C 
,g 
~ 
)( 
w 
5mM Glucose (51'n:la-d M199 media 
M199 +25mM Glucose in M199 
650 700 
25mM rrin.,s Coorol 
' ' ' . ' ' ' ' 
::: E~Hig~ - C~ntr~I :::::i::::::::t:::::/::::::: 
·.·······················-············ · ,········.-·-------,-········,········ 
-j, • ------ • -:- • • • • • • •• -:-- • • • • • • - ❖-- - - - - • - ~- • - • • • • • i • • •• ·····1 · · -· -----~ -· .. · ... 
:~:::::::::~::::::::r:::::::r·······::.:::::::::::::::::::::::::::::::::::: 
-~ ..... ----:- .. -. -----. -. ~- ....... ~- .. ------+----· -... i ..... .. --~ ....... . 
.: ......... : ........ : .. ....... : : : : ..... : 
-~·······••:----·····~------··· ········i·········t-·-------1---····· ·t········ 
·l.::::::::i::::::::i:•·:: .. ••i-••······j·········:·········:·········l········ 
r:::::::::::::··:::_:::::::::::::::::}:::::::::::::::::::::::::::}:::::::: 
: ·······i· .. ······i·········i·········i--·······i·········f·········f········ 
21""""6 
"""""" 
7178+005 
021 .. 00, 
000..00, 
-.ax, 
·"""""" 
·-
17-a>7 
11s..<Xl7 
·-
-1-
·-
·-
"''°""' 
-
·-
·-
·-
·"""°"' 
.100,.00, 
M199 +15mM Glucose in M199 
e 
C 
r 
I 
ill 
300 350 400 450 500 550 600 650 700 
Emissior(nm) 
15mM minus Control 
300 350 400 450 500 550 600 650 700 
Emission(nm) 
25mM rrinJS 15mM 
llX»001 
300 350 400 450 500 550 600 650 700 300 350 400 450 500 550 600 650 700 
Errission(nm) Errission(nm) 
-
.000.001 
.,,o,.in 
.000.001 
.-.001 
.000.001 
Figure 1. Excitation emission matrices. A: Control. B: 15mM Glucose. C: 25mM Glucose. D: 15mM minus control. 
E: 25mM minus control. F: 25mM minus 15mM. 
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UV quartz imaging (inset) chambers were obtained (NSG Precision Cells, Farmingdale, 
NY). The chamber volume is 360µL with a 1mm light path, inner 
length of38mm, and inner width of 10mm. The imaging chamber has 
a detachable quartz cover. A schematic of the chamber is shown to 
the right. Collagen gels were polymerized at 37°C directly in the imaging chambers. For 
this study we used a collagen minus and rhTG2 (recombinant human transglutaminase 2, 
N-Zyme Biotech, Darmstadt, Germany) minus negative control in addition to an rhTG2 
minus negative control. The experimental group was rhTG2 positive. The collagen· 
/rhTG2" control was measured with n = 3, the rhTG2"/collagen+ control was measured 
with n = 3 while the rhTG2+ /collagen+ experimental condition was measured with n = 7. 
Mean EEMs of each group of scans are shown in Figure 2, A-C while differences in 
means plots are shown in Figure 2, D-F. 
Extensive data analysis was performed to try and identify differences in optical signatures 
at numerous excitation and emission wavelengths. The overall conclusion was that there 
were not significant differences identified between the three groups for further 
development using endogenous fluorescence signatures. We then tried using multiphoton 
microscopy to see if we could identify qualitative differences between the 
collagen+/rhTG2" and collagen+/rhTG2+ groups. The samples were imaged with a 150 fs 
pulsed titanium-sapphire laser (Mira 900, Coherent, Santa Clara, CA) coupled to a laser-
scanning confocal microscope (LSM 510, Carl Zeiss, Jena, Germany). Incident light was 
focused and emitted signals were collected with a 40X 1.3 NA oil immersion objective 
(Carl Zeiss). The laser was centered at either A.inc= 720 nm or A.inc= 780 nm and 2PEF 
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Figure 2. Excitation emission matrices. A: Mean of collagen-/rhTG2· controls (n=3). B: Mean of collagen• rhTG2· 
controls (n=3). C: Mean of collagen•JrhTG2• experimental group (n=7). D: Mean of collagen•JrhTG2- minus mean 
of collagen-/rhTG2-. E: Mean of Colagen•/rhTG2• minus mean of collagen-/rhTG2-. F: Mean of collagen•/rhTG2• 
minus mean of collagen•JrhTG2-. 
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signals were collected in the epi-fluorescence configuration through a custom 
multiphoton filter ( 480 - 580 nm, Chroma, Rockingham, VT) and onto a non-descan 
PMT detector (based on R6357, Hamamatsu, Hamamatsu City, Japan). Similarly, the 
SHG signal was collected onto a second non-descan PMT detector through a custom 
SHG filter (380 - 400 nm, Chroma). We concluded that there was not a significant 
difference in 2PEF to be useful for detecting differences in collagen crosslinking. In 
addition, evaluation of the crosslinking extent using SHG did not prove fruitful as 
expected due to lack of evidence of differences using fluorescence spectroscopy. The 
collagen gels were also quite inconsistent in makeup. Figures 3-6 show representative 
fields of view illustrating which proved to make it difficult to note differences between 
the groups evaluated. One might argue that there are differences in the images shown, 
however, we could not rule out experimental issues such as temperature, compression of 
the gels, time exposed to laser light etc. An interesting phenomenon that we observed 
while performing SHG on the samples in that the 2PEF observed increased dramatically 
as the samples were exposed to room temperature for longer periods of time (Figure 7). 
There appears to be significant co-localization of the 2PEF signal and the SGH signal 
which might indicate increased crosslinking as a result of the longer exposure time to the 
laser, cooling to room temperature or some other unforeseen phenomenon. As a 
consequence of this observation, the experiment could be repeated in a more controlled 
manner that accounts for experimental factors. 
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Figure 3. Collagen•/rhTG2· 720nm excitation, 40x objective, zoom factor 2 
Figure 4. Collagen•/mTG2• 720nm excitation, 40x objective, zoom factor 2 
Figure 5. Collagen•/rhTG2· 780nm excitation, -40x objective, zoom factor 2 
Figure 6. Collagen•/mTG2• 780nm excitation, 40x objective, zoom factor 2 
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Figure 7. Collagen•JrhTG2• 780nm exc~ation, 40x objective, zoom factor 2. Left is 5 
minutes after removing gel from incubator at 37°C, middle is approximately 20 minutes 
while the right image is an hour. Bottom image is the image on the right but has been 
colored to emphasize co-localization (yellow) of 2PEF signal *red) wijh SHG (green). 
Future Directions 
A third method of collagen crosslinking involves enzymatic crosslinking of collagen 
based on the overexpression of lysyl oxidase. Lysyl oxidase overexpressing cells can be 
obtained as previously described [65]. Briefly, human lysyl oxidase clone (OriGene, 
Rockville, MD) are cloned into a commercially available mammalian vector, PCMV6-
XL% (OriGene). Vascular smooth muscle cells are seeded into 6-well plates at a 
concentration of 75,000 cells per well. Twelve hours following seeding, 3µL of FuGENE 
6 cationic liposome formulation (Roche Biochemical, Indianapolis, IN) is added to 
IO0µL of serum-free DMEM (GIBCO, Grand Island, NY) and allowed to incubate at 
room temperature for 5min. 3 µg of plasmid DNA is added to the mixture and allowed to 
incubate at room temperature for 15 min. The Fugene 6/DNA complex is added to each 
well. Cells are incubated with Fugene 6/DNA complex for 9 hours at which time fresh 
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medium is added. As a control, seeded wells receive the plasmid DNA vector with no 
lysyl oxidase cDNA. Culture media is collected and used to supplement standard media 
when culturing micro vessel constructs. This experimental design is inherently less clean 
than being able to add a purified enzyme directly to the gels as in the transglutaminase 
procedure so care would need to be taken to control for this and while interpreting data 
obtained from such experiments. 
Further experiments could be done with glycation to definitively determine if there 
indeed is no endogenous fluorescence signatures associated with crosslinking of collagen 
by either method. Since molding the gels in the imaging chamber and then removing 
them proved problematic, one might devise a strategy in which a custom imaging 
chamber was manufactured which is significantly thicker, at least 2mm which would be 
an improvement over the existing 1mm thickness from current imaging chambers. With 
this approach, one could incubate the gels in the appropriate media for weeks and the gels 
should be strong enough to be placed back into the imaging chamber for spectroscopy. In 
addition, mechanical testing might be utilized to help determine if crosslinking had 
occurred via increased mechanical strength. 
Future work for transglutaminase crosslinking could be performed by utilizing 
mechanical testing methods to determine if the transglutaminase procedure is working. 
We used a procedure which had been reported to increase the mechanical properties via 
transglutaminase crosslinking [64], however, we do not have proof that the technique 
actually crosslinked our collagen gels. As a consequence, our negative results may be due 
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to experimental error. For simplicity, one could also use any of the available chemical 
assays for validation of the experimental protocol as well. 
MMP: Localization 
Background and Motivation 
Matrix metalloproteinases (MMPs) are a large family of enzymes which regulate the 
extracellular matrix (ECM) composition. Between the >25 MMPs identified to date, 
virtually any component of the ECM can be cleaved [68]. All MMPs contain a propeptide 
and a zinc catalytic domain as well as a conserved methionine [69]. MMPs along with 
their inhibitors and activators are heavily studied and have been shown to be involved in 
numerous aspects of cancer biology, recent references [70-75]. MMPs are also linked to 
angiogenesis which is one of the hallmarks of cancer [70-76]. Our intent is to study 
angiogenesis and not necessarily cancer, which are often linked as can be seen in the 
previous references. Several models exist to test angiogenesis which is defined as the 
growth of new blood vessels from pre-existing vessels. Most early work was performed 
in cell culture while more recent work has utilized methods such as the mouse aortic ring 
model [77-80], culturing endothelial cells within three-dimensional fibrin gels [81], or the 
use of microvessel fragments suspended within a three-dimensional collagen lattice [24, 
28]. It has been thought that MMP-2 and MMP-9 play an important role in angiogenesis 
and there is abundant evidence in the literature which supports this. In addition to MMP-
2 and MMP-9, other MMPs are being linked to angiogenesis including MTl-MMP 
(MMP-14) which is emerging as a potentially major player in angiogenesis [77, 81, 82]. 
Molecular methods have shown the presence and activity of MMP-2, MMP-9 and MTl-
17 
MMP but, to our knowledge, there have been no studies which show localization of the 
respective MMPs or localization of their respective activity. Using the microvessel 
fragment model, we can visualize localization of the MMPs of interest using en bloc 
immunostaining and fluorescence confocal microscopy. 
Results 
Microvessel constructs were stained at various timepoints within the range in which the 
constructs actively sprout and elongate (day 3 through day 10). We anticipated a 
differential expression of the MMPs involved based on preliminary data by the Hoying 
lab which performed DNA microarray analysis illustrating a change in gene expression of 
both MMP-2 and MMP-9 (unpublished data). The constructs were stained by en bloc 
immunostaining according to the protocol developed by our lab (See Appendix). Since 
we wanted to visualize all three of the chosen MMPs at once, we needed to choose our 
stains carefully to avoid spectral overlap of the fluorescence signals. We settled on Alexa 
Flour 488, 546, and 647 (Molecular Probes, Eugene, OR) with excitation/emission 
spectra shown in Figure 8. MMP-14 was stained with Alexa Fluor 488, MMP-2 with 
Alexa Fluor 546 and MMP-9 with Alexa Fluor 64 7 for all experiments. 
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Day 3 constructs should show limited if no sprouting at all. Day 3 staining showed the 
presence of all three MMPs while vessel sprout had not yet begun (Figures 9). MMP-14 
is shown in blue, MMP-2 is shown in green and MMP-9 in red. MMP-14 and MMP-2 are 
present to a much greater degree than MMP-9 but one cannot say much about this as the 
lasers were tuned in such a way as to maximize the signal from each without saturating 
the detectors which does not account for quantum efficiency of the fluorescence tag. SHG 
shows condensation around the microvessel fragments consistent with work done 
previously [25]. One of the pitfalls of the immunostaining protocol is the use of Triton 
XI00 which is a detergent that permeabilizes the membranes of cells which leads to the 
potential staining of internal stores ofMMPs. This is most likely the cause of the majority 
of fluorescence signals generated. Speculation is that the MMPs are not concentrated 
enough in one area in the surrounding matrix to stain effectively. Studies were planned in 
which Triton XI 00 was omitted but have not been performed to date. Day 4 is when the 
constructs should just be starting to sprout. Staining of day 4 constructs showed 
concentration of MMP-14 and MMP-9 along the border of the microvessel fragment 
while MMP-2 remained diffuse within the boundaries of the fragment. 
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Figure 9. Day 3 construct staining. Upper left, combined MMP-14 (blue), MMP-2 (green), MMP09 (red), SHG 
(white). Upper right, MMP-14, Lower left, MMP-2, Lower right, MMP-9. 
SHG on day 4 constructs was much as it was on day 3, condensed along the border of the 
microvessel fragment. An interesting phenomenon in which very thin protrusions of the 
membrane was noted which only stained for MMP-14. We have speculated that these 
protrusions are filopodia which are extending into the matrix in an effort to identify the 
best route for extension of a neovessel sprout. We have noted this only in day 4 
constructs suggesting that this is an early event in sprouting using our model. Upon close 
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inspection of the SHG signals in the region of filopodia activity, one can see very thin 
collagen fibrils that may be aligning with the direction of filopodia as well as in the 
projected direction of filopodia extension (Figure 10). 
Figure 10. Day 4 construct. Areas indicated by arrows show possible alignment with collagen fibers . 
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Figure 11 shows what appear to be filopodia interescting between two parent vessel 
fragments and note that only MMP-14 stains these (Figure 12). Figure 13 shows a 
similar phenomenon in a separate experiment. One can see that these filopodia are 
extending in several places from the parent vessels but it is unclear as to whether they are 
proceeding along collagen fibers or not. Since this seems to be a rare phenomenon, we 
would like to repeat this experiment with better SHG contrast and without Triton XlOO. 
These two changes should help to clarify what is happening. 
Figure 11. Day 4 construct Z stack which shows the 3D extent of philopodia protruding from two parent vessels. From top left to bottom right is 
approximately 30µm. Interestingly, some of the philopodia appear to be extending in the direction of the opposite parent vessel. 
Day 7 constructs should have abundant sprouting with some which have undergone 
extension. Figure 14 shows a day 7 construct illustrating a medium size sprout coming 
from a parent vessel. 
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Figure 12. Tricolor staining of day 4 construct MMP-14 (blue), MMP-2 (green), MMP-9 (red) illustrating that only MMP-14 stains the "filopodia". 
Figure 13. Day 4 construct. Left is combined image with MMP-14, MMP-2, MMP-9 (blue, green, red) and SHG in white. The thin extensions stain for MMP-14 
only as indicated by a comparison of the middle image (MMP-14) and the right image (MMP-2 and MMP-9). 
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Figure 14. Day 7 construct showing a medium 
sized sprout with all three MMPs being present 
with MMP-14 more concentrated on the surface 
of the sprout. 
The sprout shows MMP-14, MMP-2 and MMP-9 staining indicating that all three are 
involved in the sprouting process. At the very tip of the sprout (Figure 15), MMP-14 
appears to be present to a much greater degree than either MMP-2 or MMP-9 suggesting 
MMP-14 may play more of a role in the elongation process than MMP-2 or MMP-9. 
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Figure 15. Day 7 construct at sprout tip. MMP-14 (blue) stains stronger than MMP-2 (green) and MMP-9 (red). 
Day 10 constructs should have well developed sprouts with some being quite long as well 
as starting to develop a crude network. We encountered some trouble while staining day 
10 constructs. Prior to the staining process the constructs looked well developed, 
however, after staining the networks failed to show up. This might be contributed to the 
fixing process or to the staining protocol. Figure 16 illustrates a day 10 construct with a 
small network of sprouts as opposed to a well developed network which we expected. 
Figure 16. Day 1 O construct showing multiple sprouts emerging from either a single 
or multiple parent vessels which is unclear from the image. 
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Figure 17. Day 10 construct. Well developed sprout showing Strong MMP-14 (blue) and MMP-2 (green) staining and weak MMP-9 (red) staining. 
Figure 17 shows a day 10 construct with a fairly long and well developed sprout. 
Staining on this sprout shows a large amount of MMP-14 presence as well as MMP-2 but 
shows little MMP-9. This is of interest as day 3 constructs showed the same staining 
pattern which might suggest that the well developed sprout is starting to take on an MMP 
profile that is similar to parent vessel fragments. Also of interest is the observation that 
MMP-9 is expressed to a much higher degree in day 4 constructs indicating that MMP-9 
may be more involved during early sprout formation compared to MMP-2 with MMP-14 
staining brightly in all constructs. 
Since we hypothesized a differential staining pattern over the time course of the 
experiments, a comparison of MMP-2, MMP-9 and MMP-14 at key time points was 
assembled. Figure 18 shows a comparison between day 3, day 4, day 7 and day 10 
MMP-9 staining. MMP-9 appears to be present at low levels at all time points but day 4. 
A comparison of MMP-2 staining on the same constructs (Figure 19) shows that day 4 
staining is reduced in comparison to days 3, 7 and 10. Finally, a comparison of MMP-14 
staining on the same constructs (Figure 20) shows about the equivalent staining pattern 
in days 3 and 4 which started to become more pronounced by day 7 ending in a much 
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more pronounced staining of the well developed sprout in the day 10 construct. The 
significance of these observations is yet to be determined, however, the data do provide 
encouraging evidence of differential MMP presence along the time points observed. 
Figure 18. MMP-9 staining patterns of constructs at different times in the sprouting process. Day 4 
appears to stain more prominently compared to the other days. 
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Figure 19. MMP-2 staining patterns of constructs at different times in the sprouting process. Day 4 
appears to stain less prominently than the other days. 
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Figure 20. MMP-14 staining patterns of constructs at different times in the sprouting process. MMP-14 
staining appears to becomes more and more prominent as the sprout grows in size. 
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Future Directions 
At first, we though it would be most prudent to stain for MMPs during three distinct 
times of the sprouting process, day 4, day 7 and day 10 corresponding to early, mid and 
late sprouting of the microvessel fragments. This was based on the belief that MMP-2 
and MMP-9 would show different staining patterns based on preliminary DNA 
microarray data obtained by the Hoying lab (unpublished data). Staining of these 
constructs did show some differences that were consistent with this data and needs to be 
explored to a greater extent. Staining of constructs at time points continuous with sprout 
growth would be beneficial and should help to solidify the observations which are made 
by the data shown in this report. These experiments were planned but lack of constructs 
prevented them from being performed. Since antibody staining cannot be adequately 
quantified, it might prove useful to perform quantitative real-time PCR and/or western 
blot analysis along these same time points to support the findings of antibody staining. 
Additionally, improvements could be made in the fixing and staining process which 
might mitigate the problems associated with the day 10 constructs. 
MMP: Localization of Activity 
Background 
After determining the presence of MMP-2, MMP-9 and MMP-14 in the microvessel 
constructs, it will be necessary to show enzyme activity in order to prove that the 
enzymes are not merely present, but active to help bolster our knowledge of the 
involvement of each enzyme during angiogenesis within the context of our model system. 
Traditional methods for detecting MMP activity such as gelatin zymography or 
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fluorometric assays have been used successfully yet such methods do not help to localize 
the activity as a sample must be homogenized or otherwise destroyed. We would like to 
image the activity of MMPs within intact microvessel constructs so that we can show 
where along the vessels each enzyme is active and during which time points each is most 
or least active. We have envisioned a novel approach using fluorogenic substrates which 
would enable us to use advanced imaging processes to visualize the activity of each 
enzyme of interest. 
Localization of MMP activity using fluorogenic substrates. Imaging of antibody staining 
of microvessel constructs is the first step to understanding the role an enzyme might play 
during angiogenesis. In order to confirm that an enzyme is involved in the process, it is 
not nearly adequate to simply show the presence of said enzyme. It becomes necessary to 
show that the enzyme is not only present, but active. Assays that show enzyme activity in 
biological samples has been done for years and is instructive, but limited due to the 
destructive nature of the testing. Fluorogenic substrates (Calbiochem, San Diego, CA) 
have been around for over two decades and have been used to assay for enzyme activity 
using standard spectroscopy which requires the homogenization of the sample of interest 
and sufficient purification. These substrates are relatively specific and are in the 
ultraviolet (UV) region of the light spectrum typically with excitation around 270-320nm 
which is out of the range of most visible lasers. Recently, fluorogenic assays have been 
developed for the MMPs of interest using fluorescence resonance energy transfer (FRET) 
engineered substrates which allow for excitation ranges between 450-520nm (AnaSpec, 
San Jose, CA). These excitation ranges are easily attainable by standard lasers but one 
31 
major problem exists in using these substrates, specificity. FRET substrates typically 
interact with multiple MMPs which limits a researcher's ability to show specific activity 
of an enzyme of interest (Table 2). 
Product Name 
Enzolyte 520 MMP-14 Assay Kit 
Sensolyte Plus 520 MMP-9 Assay Kit 
Sensolyte 520 MMP-2 Assay Kit 
Table2 
Excitation 
490nm ±20nm 
490nm ± 20nm 
490nm ±20nm 
Emission 
520nm ± 20nm 
520nm ± 20nm 
520nm ± 20nm 
Reactivity 
MMP-1,2,7,8, 12, 13, 14 
MMP-9 
MMP-1,8,9, 12, 13, 14 
General protease activity can be obtained using products such as DQ gelatin (lnvitrogen, 
Carlsbad, CA) but again are even less specific. We have envisioned two potential 
approaches to address the problem at hand. One of the methods is to use FRET substrates 
in conjunction with real-time PCR to show which of the MMPs outlined in the product 
sheet is contributing the most to the signal observed by single photon fluorescence 
excitation. This method would help to identify the main contributor of fluorescence 
signal but might not prove fruitful if an MMP that does not interest us is the major 
contributor. One might also consider experiments where the other MMPs are inhibited by 
either antibody blockade or inhibition by one of the tissue inhibitors of matrix 
metalloproteinases (TIMP). 
A second, more theoretical approach is to use multiphoton excited fluorescence. Two 
photon excitation has been widely studied and used in recent years, however, due to the 
nature of the excitation ranges of these substrates, a standard two photon laser operating 
in the 700-l000nm range will not be capable of exciting them. In theory, three photon 
excited fluorescence will excite in the desired range. Three photon excited fluorescence 
(3PEF) has been described in the literature starting in the mid 1990 [83, 84]. We reasoned 
that three photon excitation could be used to activate fluorogenic substrates actively 
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excited in the UV range of interest by tuning the laser between 840nm and 960nm 
thereby giving us an effective range of three photon excitation of 280-320nm which 
nicely fits the range of specific fluorogenic substrates commercially available. Since 
nobody has described three photon fluorescence in these fluorogenic substrates and the 
fact that there are no three photon controls commercially available, we devised a strategy 
to test that the laser system would be able to produce three photon activity and detect it. 
We used rat tails which are rich in collagen as the test subject. The thought was that 
collagen crosslinking would somehow show up in the three photon range. Preliminary 
results showed that we could see very little 3PEF in the rat tail collagen until we used 
higher laser power and with increased exposure time. This produced some sort of optical 
effect that increased with time exposed to the laser. We filtered under 400nm and did see 
something which we concluded had to be 3PEF, though we believed this to be an artifact 
caused by prolonged laser exposure (Figure 21). 
Figure 21 . 840nm Excitation, filtered below 400nm . Left to right, 40% laser power, 60%, and 100%. Elapsed time: approximately 20 minutes. 
Future Directions 
The next step is to develop a strategy for testing the capability of the fluorogenic 
substrates to produce 3PEF. This is problematic because the manufacturers have no 
positive controls available as the substrates are synthesized in the quenched position and 
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only cleavage by the respective MMPs will activate the molecules. The strategy that 
might be best is to mix the substrate with purified and activated MMP enzyme then use 
multiphoton excitation to test for 3PEF. Once it has been verified that 3PEF is attainable 
using fluorogenic substrates, application of the substrates to living microvessel constructs 
is the next step. One approach is to apply the substrates to the constructs approximately 
24 hours prior to imaging to allow for enough substrate to be cleaved. This time period is 
purely speculative but serves as a basis from which to start. The constructs would then be 
imaged using multiphoton microscopy. There are several potential problems associated 
with this approach including contamination of the fluorescence signal by culture media, 
excessive moving of the construct could displace cleaved enzyme, destruction of the 
sample from prolonged exposure to laser etc. Initial results will help clarify problem 
points in the process. 
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Appendix 
Glycation crosslinking protocol 
Making collagen gels: 2mL final volume required for this experiment. 
1. Need 3mg/mL collagen therefore need to normalize from a more concentrated solution 
Jmg/mL x2.0mL =l.327mL 
4.32mg/mL 
2. lx Hanks medium (starting cone. 1 Ox) therefore need 200µL 
3. 20mM HEPES therefore need 40µL HEPES 
4. Add sterile H2O to 2mL 
1.327mL collagen 
.2mLHanks 
.04mLHEPES 
.433mLH2O 
5. pH to ~7.4 using lM NaOH 
8 gels loaded into a 48 well plate (~200µL per gel) 
6. Incubate gels at 37C for 30 minutes or until set 
7. Place media on gels, 4 concentration of glucose were used along with m 199 reagent 
8. No glu added in first two wells (5mM glu standard with m199 reagent) 
9. 15mM glu in m199 added to 3rd and 4th wells 
Glu FW = 180.16g/mole 
.15mM solution= 180.16g/mole x lmole/lO00mL = .18016g/mL x .015 = .0027 or 
2.7mg/mL etc (30mM and 50mM concentrations calculated similarly) 
10. 30mM glu in m199 added to 5th and 6th wells 
11. 50mM glu in m199 added to 7th and 8th wells 
Gels incubated for 4 weeks at ~4C 
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En bloc immunostaining protocol 
I. Remove microvessel fragment gels from well plates and place in micrfuge tube. 
2. Wash briefly in Ix PBS. 
3. Fix by incubating gels in 2% paraformaldehyde in Ix PBS for 15 minutes. 
4. Place gels in fresh PBS until ready to use. 
5. Incubate constructs in .25% triton XlO0 in DCF-PBS for 10 minutes. 
6. Wash in DCF-PBS for 5 minutes. 
7. Add 3 drops of Image II signal reducer and incubate for 30 minutes. 
8. Remove Image II signal reducer and add 1 00µL 10% goat serum and incubate for 30 
minutes. 
9. Mouse IgG3 anti-MMP-14 monoclonal antibody (Chemicon, Temecula, CA) was 
added at a 1 :500 concentration in DCF-PBS and incubated for 2 hours. 
10. Wash in DCF-PBS 2x for 5 minutes and Ix for 60 minutes. 
11. Goat anti-mouse IgG3 tagged with Alexa Fluor 488 (Molecular Probes, Eugene, OR) 
was added at a 1 :500 concentration in DCF-PBS and incubated for 1 hour then 
washed in DCF-PBS 2x for 5 minutes and Ix for 60 minutes. 
Zenon Mouse lgG labeling kit (Molecular Probes, Eugene, OR) was used/or staining 
with MMP-2 and MMP-9 
12. Add 1 µL anti mouse lgG1 MMP-2 monoclonal antibody (Chemicon, Temecula, CA) 
to 5µL Alexa Fluor 555 (Molecular Probes, Eugene, OR). 
13. Add 3.2µL anti mouse IgG1 MMP-9 monoclonal antibody (Chemicon, Temecula, 
CA) to 5µL Alexa Fluor 647 (Molecular Probes, Eugene, OR). 
14. Incubate both for 5 minutes. 
15. Add 5µL Zenon blocking reagent (Molecular Probes, Eugene, OR) to both and 
incubate for 5 minutes. 
16. Add each mixture to 500µL DCF-PBS. Use 250µL of each per construct. 
17. Incubate overnight. Wash in DCF-PBS 2x for 5 minutes and Ix for 60 minutes. 
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Transglutaminase crosslinking protocol 
Obtain transglutaminase from n-zyme inc 
Making collagen gels: lmL final volume required for this experiment. 
1. Need 3mg/mL collagen therefore need to normalize from a more concentrated solution 
3mg I ml xl .0mL = .694mL 
4.32mg/mL 
2. Ix Hanks medium (starting cone. lOx) therefore need I00µL 
3. 20mM HEPES therefore need 20µL HEPES 
4. Add sterile H2O to 2mL 
.694mL collagen 
.lmLHanks 
.02mLHEPES 
.217mL H2O 
5. pH to ~7.4 using IM NaOH 
6. aliquot the gels into 2 sets of 400µL each 
7. 2 vials add nothing 
8. 2 vials add 5000: 1 transglutaminase to collagen 
9. load into a 48 well plate (~200µL per gel) 
10. Incubate gels at 37C for 30 minutes or until set 
11. Image gels 
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Rat Fat Microfragment (RFMF) Isolation Protocol 
Required Supplies 
Solutions (sterile) instruments (sterilized) 
- 250ml of 0.1% BSA in DCF-PBS (BSA-PBS) [ ] - surgical pack: 4" gauze (x2 per rat), 1 large sci-
- 30ml of BSA-PBS in 50ml tube 
· - 21 g/ml Type 1 collagenase and 1mg/ml 
D Ase in BSA-PBS (col-D Ase-PBS) 
·•make 1. 5x 110/ume of collected fat 
calcuf;Jtions in step 2a 
sors, 1 small scissors, 1 hemostat, 1 forceps 
[ ] - mincing pack: 1 cuNed scissors, 1 forceps 
[ ) - metal rack to support 30µ1 screen 
[ ] - 50ml polycarbonate flask •. w/ stir-bar (x1 ~ er 
6ml collected fat) 
- type 1 rat tail collagen (greater than 3mg/ml) [ ) - 2 screens (30µ and 500µm) 
. - 1M NaOH 
- sterile 'lo 
[ ) - 100mm x 20mm petri dishes x4 
(NOT TISSUE CULTURE TREATED) 
[ ) - 50ml centrifuge tubes x3 
see recipes@ end: [ ] - 15ml centrifuge tubes x.3 
- 4x DMEM (less than 1 week old) [ ) - 10ml syringe 
. - RFMF media (ma e fresh each time) [ ) - 0 .2µm syringe fil ter ( 1 x 15ml coJ-DNAse-PBS) 
[ ) - 48 well plate 
I I - steri le 10ml pipettes 
1. Surgery (need surgical pack, 30ml of BSA-PBS in 50ml tube) 
a. Anesthetize ani al with lsofl orane, then inject inter-peritoneal with 1.5ml 
embutol (see illustration 1 ). 
b. Once animal is anesthetized, spray ab 0 1 en with Nolvasan. 
c. Clamp s in, just below penis, with hemostat. Begin incision with large 
scissors, starting in the center and cutting laterally (see illustration 1 ). 
d. Place 2 folded steri le gauze pads below incision (see illustration 2). 
e. IJ\/ith small scissors, ake a small incision into each scrotu , exposing the 
epidydimat fat. 
f. 'Nith orceps, carefully remove the testes and epidydimal fat pads from the 
ani al and place on sterile gauze. (illustration 2) 
g. V.Jith creeps, pull the fat from the testes amj cut using the small scissors. 
h. Carel Hy place removed fat into 50 L tube with BSA-PBS. 
Final volume of fat + BSA-PBS - 30ml = fat volume 
2. RFMF isolation (need BSA-PBS, mincing pack, water bath set to 37°C, 
metal rack, 30pm and 500pm screens, flasks w/ stir-bars, petri-dishes, 
50ml and 15 L centrifuge tubes, 48 well plate, syringe and s~1ringe 
filter, sterile 10ml pipettes) 
illustra ·on 1 
illustration 2 
38 
a. Mea5 re collagenase and DNAse. • NOTE : combine collagenase and DNAse in same 50ml tu e, 
keep in freezer unti l use• 
collagenase (mg) = fat volume x :3 
DNAse (mg) = fat volume x 1. 5 
BSA-PBS (ml) = fat volume x 1.5 • NOTE : do not add BSA-PBS until step c"' 
b. Place all the tat in a petri dish. Mince with curved scissors for 10 minutes. When finished, fat should not 
clog tip of 10 L pipette. 
c. Mix step (1 components (col-DNAse-PBS) in 50ml tube, sterilize with syringe filter into petri dish. Mix 
gently with scissors. 
d. Divide rat fat-col-DNAse-PBS evenly into 50n L polycarbonate flasks. Agitate briskly for 6 min in 37"'C 
water bath. Vt/hen finished, there should be only a few s all fat particulates visible wtin the flask. 
e. Divide rat fot-col-DNAse-PBS evenly into two 50ml centrifuge tubes (if small volume, 15ml tubes 
may be used instead). Centrifuge at 400rcf tor 4 minutes. 
f. Caret Uy decant (or pipette if preferred; supernatant and adipocytes (be sure to not disturb pellet at 
botto1 of tube). 
g. Add 10ml of BSA-PBS to each tube . Gently titrate against side of tube to break up pellet 4x. Trans1er 
everything evenly to two 15ml tubes. Centrifuge at 400rcf for 4 minutes. 
h. Repeat f and g 2x 
i. During last spin, presoak 30µm screen in ~-20ml BSA-PBS within a covered petri dish. With sterile 
forceps, place 500µm screen above petri dish and presoak with ~5ml BSA-PBS pipetted on top of 
screen. 
j. Aspirate fragment suspension a few times and then slowly pipette over 500µm screen. Move outward 
from ce, ter in concentric circles. W en finished, rinse tube with ~5ml BSA-PBS and pipette over 
screen in similar manner. Discard 50011m screen. 
k. \JVith sterile rceps, place wire mesh on top of petri dish. The, center 
30tim screen on wire mesh. 
Pipette filtered fragment suspension over 30µm screen in concentric 
circles. Take care to prevent 
s spension from spilling over the sides of the screen. 
I. Rinse the screen gently with 5ml BSA-PBS. 
m. 1/v'ith sterile forceps, slide 30µm screen from wire mesh into petri dish with 
20ml BSA-PBS. Gently shake petri dish to dislodge frag ents from 
the screen. 
n. Place the ack of the petri dish on the lid (angling the dish forward). With 
force s, grab the top of the screen and slowly raise from the petri di1:.,h. 
Simultaneously, use 101 L of BSA-PBS an rinse the screen with a 
bac -and-forth motion. (see illustration 3) 
o. Collect t e filtered fragment-BSA-PBS suspension an ispense into a 
50ml tube. 
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p. To count fragments, clip ~20% off the end of a 200µL pipette tip. Gently shake the 50ml tube 
containing the fragment-BSA-PBS suspension. Remove two 20µL samples of suspension and 
dispense on a glass slide or petri dish lid. Under a microscope, count the fragments: 
Total Fragments = (ave fragment count) • (total ml suspension in 50ml tube) • 50 
q. Centrifuge fragment-BSA-PBS suspension at 400rcf for 4 minutes. Carefully decant or aspirate the 
supernatant. Leave .... 200µ1.. above the pellet. 
3. Suspend RFMFa In collagen (need 48 well plate, 4x OMEM, 1 M NaOH, Sterile Hz(), Type 1 Rat Tail 
Collagen, bucket of ice, RFMF Media) 
a. Place 4x OMEM. 1 M NaOH, Sterile Hz(), Type 1 Rat Tail Collagen, and a 15ml tube into ice bucket. 
b. Determine total collagen suspension volume required for [RFMF] of 15,000 - 20,000 RFMF / ml. Add 
an extra 0.5 to 1ml to compensate for tube and pipette wall adhesion. Final [collagen] is 3mg/ml. 
i. Determine volume of collagen required to yield 3mg/ml 
ii. Determine volume of 4x DMEM = collagen volume/ 3 
iii. Determine volume of water= (final total volume) - (collagen volume) - (4x DMEM volume) 
iv. Add SMALL volumes 1 M NaOH until appropriate suspension pH (mixture color) is reached 
c. Gently flick 50mL tube to break up RFMF pellet Slowly dispense collagen suspension. Take care to 
avoid introducing bubbles. Pipette until fragments are fully suspended. Add additional NaOH if 
required. 
d. Pipette fragment-collagen suspension into 48-well plates. Add 250µL per well. 
e. Place well plate in sterile incubator (37"C, 5% COz) for 20 minutes. 
f. Add 250µL of RFMF media to each wen. Place well plate back into incubator. 
g. Change media every 4 days. Fragments should show appreciable sprouting by day 4. 
Media Recipes 
RFMFmedia: 
9ml 1x DMEM media (VWR 10-014-CV, lnvitrogen 11885-084) 
1 ml heat inactivated Fetal Bovine Serum 
•• make fresh and filter sterilize before each use 
4x DMEM: 
tg GIBCO DMEM powder (lnvttrogen 31600-034 or 026) 
0.37g NaHCOJ 
0.476g HEPES (sigma H7006) 
add Sterile HzO to bring volume up to 25ml 
••tilter sterilize before use 
••make new 4x DMEM every 7 days 
40 
References 
1. Fisher, C., et al., Interstitial collagenase is required for angiogenesis in vitro. Dev 
Biol, 1994. 162(2): p. 499-510. 
2. Haas, T.L., S.J. Davis, and J.A. Madri, Three-dimensional type I collagen lattices 
induce coordinate expression of matrix metalloproteinases MTJ-MMP and MMP-
2 in microvascular endothelial cells. J Biol Chem, 1998. 273(6): p. 3604-10. 
3. Jain, A., et al., Production of cytokines, vascular endothelial growth factor, 
matrix metalloproteinases, and tissue inhibitor of metalloproteinases 1 by 
tenosynovium demonstrates its potential for tendon destruction in rheumatoid 
arthritis. Arthritis Rheum, 2001. 44(8): p. 1754-60. 
4. Risau, W., Mechanisms of angiogenesis. Nature, 1997. 386(6626): p. 671-4. 
5. Vernon, R.B. and E.H. Sage, A novel, quantitative model for study of endothelial 
cell migration and sprout formation within three-dimensional collagen matrices. 
Microvasc Res, 1999. 57(2): p. 118-33. 
6. Ausprunk, D.H. and J. Folkman, Migration and proliferation of endothelial cells 
in preformed and newly formed blood vessels during tumor angiogenesis. 
Microvasc Res, 1977. 14(1): p. 53-65. 
7. Adams, R.H., et al., Roles of ephrinB ligands and EphB receptors in 
cardiovascular development: demarcation of arterial/venous domains, vascular 
morphogenesis, and sprouting angiogenesis. Genes Dev, 1999. 13(3): p. 295-306. 
8. Breier, G., Angiogenesis in embryonic development--a review. Placenta, 2000. 21 
Suppl A: p. Sll-5. 
9. Holmgren, L., et al., Angiogenesis during human extraembryonic development 
involves the spatiotemporal control of P DGF ligand and receptor gene 
expression. Development, 1991. 113(3): p. 749-54. 
10. Battegay, E.J., Angiogenesis: mechanistic insights, neovascular diseases, and 
therapeutic prospects. J Mol Med, 1995. 73(7): p. 333-46. 
11. Bray, R.C., R.M. Rangayyan, and C.B. Frank, Normal and healing ligament 
vascularity: a quantitative histological assessment in the adult rabbit medial 
collateral ligament. J Anat, 1996. 188 ( Pt 1): p. 87-95. 
12. Bray, R.C., et al., Vascular response of the meniscus to injury: effects of 
immobilization. J Orthop Res, 2001. 19(3): p. 384-90. 
13. Ravanti, L. and V.M. Kahari, Matrix metalloproteinases in wound repair 
(review). Int J Mol Med, 2000. 6(4): p. 391-407. 
14. Blavier, L., et al., Tissue inhibitors of matrix metalloproteinases in cancer. Ann N 
Y Acad Sci, 1999. 878: p. 108-19. 
15. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat 
Med, 1995. 1(1): p. 27-31. 
16. Grant, D.S., et al., Decorin suppresses tumor cell-mediated angiogenesis. 
Oncogene, 2002. 21(31): p. 4765-77. 
17. Valente, P., et al., TIMP-2 over-expression reduces invasion and angiogenesis 
and protects B16FJ0 melanoma cells.from apoptosis. Int J Cancer, 1998. 75(2): p. 
246-53. 
41 
18. Vergani, V., et al., Inhibition of matrix metalloproteinases by over-expression of 
tissue inhibitor of metalloproteinase-2 inhibits the growth of experimental 
hemangiomas. Int J Cancer, 2001. 91(2): p. 241-7. 
19. Henriet, P., L. Blavier, and Y.A. Declerck, Tissue inhibitors ofmetalloproteinases 
(/'IMP) in invasion and proliferation. Apmis, 1999. 107(1): p. 111-9. 
20. Rivilis, I., et al., Differential involvement of MMP-2 and VEGF during muscle 
stretch- versus shear stress-induced angiogenesis. Am J Physiol Heart Circ 
Physiol, 2002. 283(4): p. H1430-8. 
21. Tranqui, L. and P. Tracqui, Mechanical signalling and angiogenesis. The 
integration of cell-extracellular matrix couplings. C R Acad Sci III, 2000. 323(1 ): 
p. 31-47. 
22. V ailhe, B., et al., In vitro angiogenesis is modulated by the mechanical properties 
of fibrin gels and is related to alpha(v)beta3 integrin localization. In Vitro Cell 
Dev Biol Anim, 1997. 33(10): p. 763-73. 
23. Vernon, R.B. and E.H. Sage, Contraction offibrillar type I collagen by 
endothelial cells: a study in vitro. J Cell Biochem, 1996. 60(2): p. 185-97. 
24. Hoying, J.B., C.A. Boswell, and S.K. Williams, Angiogenic potential of 
microvessel fragments established in three-dimensional collagen gels. In Vitro 
Cell Dev Biol Anim, 1996. 32(7): p. 409-19. 
25. Kirkpatrick, N.D., et al., Live imaging of collagen remodeling during 
angiogenesis. Am J Physiol Heart Circ Physiol, 2007. 292(6): p. H3198-206. 
26. Krishnam L, H.J., Das R, Weiss JA. Alterations in the material properties of 
collagen by angiogenesis. in Proc 49th Annual Orthopaedic Research Society 
Meeting. 2003. 
27. Krishnan L, H.J., Nguyen H, Song H, Weiss JA, Interaction of angiogenic 
microvessels with the extracellular matrix in an in vitro model. American Journal 
of Physiology: Heart and Circulation, 2007. In review. 
28. Shepherd, B.R., et al., Rapid perfusion and network remodeling in a 
microvascular construct after implantation. Arterioscler Thromb V asc Biol, 2004. 
24(5): p. 898-904. 
29. Bergers, G. and S. Song, The role of pericytes in blood-vessel formation and 
maintenance. Neuro Oncol, 2005. 7(4): p. 452-64. 
30. Egginton, S., et al., The role of pericytes in controlling angiogenesis in vivo. Adv 
Exp Med Biol, 2000. 476: p. 81-99. 
31. Lafleur, M.A., et al., Perivascular cells regulate endothelial membrane type-I 
matrix metalloproteinase activity. Biochem Biophys Res Commun, 2001. 282(2): 
p. 463-73. 
32. Ozerdem, U. and W.B. Stallcup, Early contribution ofpericytes to angiogenic 
sprouting and tube formation. Angiogenesis, 2003. 6(3): p. 241-9. 
33. Redmer, D.A., et al., Evidence for a role of capillary pericytes in vascular growth 
of the developing ovine corpus luteum. Biol Reprod, 2001. 65(3): p. 879-89. 
34. Saito, M., et al., Single-column high-performance liquid chromatographic-
fluorescence detection of immature, mature, and senescent cross-links of 
collagen. Anal Biochem, 1997. 253(1): p. 26-32. 
35. Greenwald, S.E. and C.L. Berry, Improving vascular grafts: the importance of 
mechanical and haemodynamic properties. J Pathol, 2000. 190(3): p. 292-9. 
42 
36. Hirai, J. and T. Matsuda, Self-organized, tubular hybrid vascular tissue composed 
of vascular cells and collagen for low-pressure-loaded venous system. Cell 
Transplant, 1995. 4(6): p. 597-608. 
37. L'Heureux, N., et al., In vitro construction of a human blood vessel from cultured 
vascular cells: a morphologic study. J Vase Surg, 1993. 17(3): p. 499-509. 
38. Weinberg, C.B. and E. Bell, A blood vessel model constructed from collagen and 
cultured vascular cells. Science, 1986. 231(4736): p. 397-400. 
39. Balgude, A.P., et al., Agarose gel stiffness determines rate of DRG neurite 
extension in JD cultures. Biomaterials, 2001. 22(10): p. 1077-84. 
40. Bell, E., et al., Living tissue formed in vitro and accepted as skin-equivalent tissue 
of full thickness. Science, 1981. 211(4486): p. 1052-4. 
41. Lafrance, H., et al., Study of the tensile properties of living skin equivalents. 
Biomed Mater Eng, 1995. 5(4): p. 195-208. 
42. Michel, M., F.A. Auger, and L. Germain, Anchored skin equivalent cultured in 
vitro: a new tool for percutaneous absorption studies. In Vitro Cell Dev Biol 
Anim, 1993. 29A(l 1): p. 834-7. 
43. Wilkins LM, W.S., Prosky SJ, Meunier SF, Parenteau NL, Development of a 
bilayered skin construct for clinical applications. Biotechnol Bioeng, 1994. 43: p. 
747-56. 
44. Mauck, R.L., et al., Functional tissue engineering of articular cartilage through 
dynamic loading of chondrocyte-seeded agarose gels. J Biomech Eng, 2000. 
122(3): p. 252-60. 
45. Toolan, B.C., et al., Effects of growth-factor-enhanced culture on a chondrocyte-
collagen implant for cartilage repair. J Biomed Mater Res, 1996. 31(2): p. 273-
80. 
46. Porter, B.D., et al., Mechanical properties of a biodegradable bone regeneration 
scaffold. J Biomech Eng, 2000. 122(3): p. 286-8. 
47. Huang, D., et al., Mechanisms and dynamics of mechanical strengthening in 
ligament-equivalent fibroblast-populated collagen matrices. Ann Biomed Eng, 
1993. 21(3): p. 289-305. 
48. Koide, T. and M. Daito, Effects of various collagen cross/inking techniques on 
mechanical properties of collagen film. Dent Mater J, 1997. 16(1): p. 1-9. 
49. Suh, H., et al., A bone replaceable artificial bone substitute: cytotoxicity, cell 
adhesion, proliferation, and alkaline phosphatase activity. Artif Organs, 2001. 
25(1): p. 14-21. 
50. Weadock, K.S., et al., Physical cross/inking of collagen fibers: comparison of 
ultraviolet irradiation and dehydrothermal treatment. J Biomed Mater Res, 1995. 
29(11): p. 1373-9. 
51. Goissis, G ., et al., The chemical protecting group concept applied in cross linking 
of natural tissues with glutaraldehyde acetals. Artif Organs, 1998. 22(3): p. 210-
4. 
52. Jayakrishnan, A. and S.R. Jameela, Glutaraldehyde as a fixative in bioprostheses 
and drug delivery matrices. Biomaterials, 1996. 17(5): p. 471-84. 
53. Kanamori T, H.T., Shinbo T, Sakai K, Difference in solute diffusivity in 
cross/inked collagen gels prepared under various conditions. Mater Sci Eng C, 
2000. 13: p. 85-9. 
43 
54. Olde Damink LLH, D.P., van Luyn MJ, van Wachem PB, Nieuwenhuis P, Feijen 
J, Glutaraldehyde as a cross/inking agent for collagen based biomaterials. J 
Mater Sci Mater Med, 1995. 6: p. 460-72. 
55. Chevallay, B., N. Abdul-Malak, and D. Herbage, Mouse fibroblasts in long-term 
culture within collagen three-dimensional scaffolds: influence of cross/inking with 
diphenylphosphorylazide on matrix reorganization, growth, and biosynthetic and 
proteolytic activities. J Biomed Mater Res, 2000. 49(4): p. 448-59. 
56. Bellincampi LD, D.M., Effect of cross/inking method on collagen fiber-fibroblast 
interactions . . J Appl Polym Sci, 1998. 63: p. 1423-28. 
57. Girton, T.S., T.R. Oegema, and R.T. Tranquillo, Exploiting glycation to stiffen 
and strengthen tissue equivalents for tissue engineering. J Biomed Mater Res, 
1999. 46(1): p. 87-92. 
58. Noishiki, Y., et al., Succinylated collagen cross/inked by thermal treatment for 
coating vascular prostheses. Artif Organs, 1998. 22(8): p. 672-80. 
59. Pieper, J.S., et al., Attachment of glycosaminoglycans to collagenous matrices 
modulates the tissue response in rats. Biomaterials, 2000. 21(16): p. 1689-99. 
60. Rault I, F.V., Herbage D, Abdul-Malak N, Hue A, Evaluation of different 
chemical methods for cross/inking collagen gels, films, and sponges. J Mater Sci 
Mater Med, 1996. 7: p. 215-22. 
61. Simmons, D.M. and J.N. Kearney, Evaluation of collagen cross-linking 
techniques for the stabilization of tissue matrices. Biotechnol Appl Biochem, 
1993. 17 ( Pt 1): p. 23-9. 
62. Wissink, M.J., et al., Endothelial cell seeding on cross/inked collagen: effects of 
cross linking on endothelial cell proliferation and fimctional parameters. Thromb 
Haemost, 2000. 84(2): p. 325-31. 
63. Aeschlimann, D. and M. Paulsson, Transglutaminases: protein cross-linking 
enzymes in tissues and body fluids. Thromb Haemost, 1994. 71(4): p. 402-15. 
64. Orban, J.M., et al., Cross/inking of collagen gels by transglutaminase. J Biomed 
Mater Res A, 2004. 68(4): p. 756-62. 
65. Elbjeirami, W.M., et al., Enhancing mechanical properties of tissue-engineered 
constructs via lysyl oxidase cross/inking activity. J Biomed Mater Res A, 2003. 
66(3): p. 513-21. 
66. Lau, Y.K., A.M. Gobin, and J.L. West, Overexpression oflysyl oxidase to 
increase matrix cross/inking and improve tissue strength in dermal wound 
healing. Ann Biomed Eng, 2006. 34(8): p. 1239-46. 
67. Speer, D.P., et al., Biological effects of residual glutaraldehyde in glutaraldehyde-
tanned collagen biomaterials. J Biomed Mater Res, 1980. 14(6): p. 753-64. 
68. Egeblad, M. and Z. Werb, New functions for the matrix metalloproteinases in 
cancer progression. Nat Rev Cancer, 2002. 2(3): p. 161-74. 
69. Chakraborti, S., et al., Regulation of matrix metalloproteinases: an overview. Mol 
Cell Biochem, 2003. 253(1-2): p. 269-85. 
70. Arvelo, F. and C. Cotte, [Metalloproteinases in tumor progression. Review]. 
Invest Clin, 2006. 47(2): p. 185-205. 
71. Deryugina, E.I. and J.P. Quigley, Matrix metalloproteinases and tumor 
metastasis. Cancer Metastasis Rev, 2006. 25(1): p. 9-34. 
44 
72. Fingleton, B., Matrix metalloproteinases: roles in cancer and metastasis. Front 
Biosci, 2006. 11: p. 479-91. 
73. Golubkov, V.S. and A.Y. Strongin, Proteolysis-driven oncogenesis. Cell Cycle, 
2007. 6(2): p. 147-50. 
74. Malemud, C.J., Matrix metalloproteinases (MMPs) in health and disease: an 
overview. Front Biosci, 2006. 11: p. 1696-701. 
75. Rosenthal, E.L. and L.M. Matrisian, Matrix metalloproteases in head and neck 
cancer. Head Neck, 2006. 28(7): p. 639-48. 
76. Hanahan, D. and R.A. Weinberg, The hallmarks of cancer. Cell, 2000. 100(1): p. 
57-70. 
77. Chun, T.H., et al., MTJ-MMP-dependent neovesselformation within the confines 
of the three-dimensional extracellular matrix. J Cell Biol, 2004. 167(4): p. 757-
67. 
78. Masson, V., et al., Contribution of host MMP-2 and MMP-9 to promote tumor 
vascularization and invasion of malignant keratinocytes. Faseb J, 2005. 19(2): p. 
234-6. 
79. Masson V Ve, D.L., Grignet-Debrus C, Bernt S, Bajou K, Blacher S, Roland G, 
Chang Y, Fong T, Carmeliet P, Foidart JM, Noel A. .Mouse Aortic Ring Assay: A 
New Approach of the Molecular Genetics of Angiogenesis. in Biol Proced Online. 
2002. 
80. Yue, P.Y., et al., The angiosuppressive effects of 20(R)- ginsenoside Rg3. 
Biochem Pharmacol, 2006. 72(4): p. 437-45. 
81. Ghajar, C.M., et al., Mesenchymal stem cells enhance angiogenesis in 
mechanically viable prevascularized tissues via early matrix metalloproteinase 
upregulation. Tissue Eng, 2006. 12(10): p. 2875-88. 
82. Genis, L., et al., MTJ-MMP: universal or particular player in angiogenesis? 
Cancer Metastasis Rev, 2006. 25(1): p. 77-86. 
83. Szmacinski, H., I. Gryczynski, and J.R. Lakowicz, Three-photon induced 
fluorescence of the calcium probe Indo-1. Biophys J, 1996. 70(1): p. 547-55. 
84. Lakowicz, J.R., Emerging applications of fluorescence spectroscopy to cellular 
imaging: lifetime imaging, metal-ligand probes, multi-photon excitation and light 
quenching. Scanning Microsc Suppl, 1996. 10: p. 213-24. 
45 
